Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial

References

• Alterman, A. I., Rutherford, M. J., Cacciola, J. S., McKay, J. R., & Woody, G. E. (1996). Response to methadone maintenance and counseling in antisocial patients with and without major depression. The Journal of Nervous and Mental Disease, 184(11), 695–702. https://doi.org/10.1097/00005053-199611000-00007
   PubMed Web of Science ®Google Scholar
• Avants, S. K., Warburton, L. A., & Margolin, A. (2000). The influence of coping and depression on abstinence from illicit drug use in methadone-maintained patients. The American Journal of Drug and Alcohol Abuse, 26(3), 399–416. https://doi.org/10.1081/ADA-100100252
   PubMed Web of Science ®Google Scholar
• Bastien, G., McAnulty, C., Ledjiar, O., Socias, M. E., Le Foll, B., Lim, R., Hassan, A. N., Brissette, S., Marsan, S., Talbot, A., & Jutras-Aswad, D., OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. (2022). Effects of buprenorphine/naloxone and methadone on depressive symptoms in people with prescription opioid use disorder: A pragmatic randomised controlled trial. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie, 68(8), 572–585. https://doi.org/10.1177/07067437221145013
   PubMed Web of Science ®Google Scholar
• Beck, A. T., Steer, R. A., & Brown, G. K. (1996). BDI-II: Beck depression inventory. Pearson.
   Google Scholar
• Belzak, L., & Halverson, J. (2018). The opioid crisis in Canada: a national perspective [La crise des opioïdes au Canada: une perspective nationale]. Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice, 38(6), 224–233. https://doi.org/10.24095/hpcdp.38.6.02
   PubMed Web of Science ®Google Scholar
• Benningfield, M. M., Dietrich, M. S., Jones, H. E., Kaltenbach, K., Heil, S. H., Stine, S. M., Coyle, M. G., Arria, A. M., O'Grady, K. E., Fischer, G., & Martin, P. R. (2012). Opioid dependence during pregnancy: relationships of anxiety and depression symptoms to treatment outcomes. Addiction (Abingdon, England), 107 Suppl 1, 74–82. https://doi.org/10.1111/j.1360-0443.2012.04041.x
   PubMed Web of Science ®Google Scholar
• Beste, L. A., Ioannou, G. N., Larson, M. S., Chapko, M., & Dominitz, J. A. (2010). Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association, 8(11), 972–978. https://doi.org/10.1016/j.cgh.2010.07.012
   PubMed Web of Science ®Google Scholar
• Blanco, C., Iza, M., Schwartz, R. P., Rafful, C., Wang, S., & Olfson, M. (2013). Probability and predictors of treatment-seeking for prescription opioid use disorders: A National Study. Drug and Alcohol Dependence, 131(1–2), 143–148. https://doi.org/10.1016/j.drugalcdep.2012.12.013
   PubMed Web of Science ®Google Scholar
• Brienza, R. S., Stein, M. D., Chen, M.-H., Gogineni, A., Sobota, M., Maksad, J., Hu, P., & Clarke, J. (2000). Depression among needle exchange program and methadone maintenance clients. Journal of Substance Abuse Treatment, 18(4), 331–337. https://doi.org/10.1016/S0740-5472(99)00084-7
   PubMed Web of Science ®Google Scholar
• Brière, F. N., Rohde, P., Seeley, J. R., Klein, D., & Lewinsohn, P. M. (2014). Comorbidity between major depression and alcohol use disorder from adolescence to adulthood. Comprehensive Psychiatry, 55(3), 526–533. https://doi.org/10.1016/j.comppsych.2013.10.007
   PubMed Web of Science ®Google Scholar
• Carrieri, M. P., Rey, D., Loundou, A., Lepeu, G., Sobel, A., & Obadia, Y., MANIF-2000 Study Group. (2003). Evaluation of buprenorphine maintenance treatment in a French cohort of HIV-infected injecting drug users. Drug and Alcohol Dependence, 72(1), 13–21. https://doi.org/10.1016/s0376-8716(03)00189-3
   PubMed Web of Science ®Google Scholar
• Conner, K. R., Pinquart, M., & Gamble, S. A. (2009). Meta-analysis of depression and substance use among individuals with alcohol use disorders. Journal of Substance Abuse Treatment, 37(2), 127–137. https://doi.org/10.1016/j.jsat.2008.11.007
   PubMed Web of Science ®Google Scholar
• Davis, L., Uezato, A., Newell, J. M., & Frazier, E. (2008). Major depression and comorbid substance use disorders. Current Opinion in Psychiatry, 21(1), 14–18. https://doi.org/10.1097/YCO.0b013e3282f32408
   PubMed Web of Science ®Google Scholar
• Dean, A. J., Bell, J., Christie, M. J., & Mattick, R. P. (2004). Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence. European Psychiatry: The Journal of the Association of European Psychiatrists, 19(8), 510–513. https://doi.org/10.1016/j.eurpsy.2004.09.002
   PubMed Web of Science ®Google Scholar
• Dixit, A. R., & Crum, R. M. (2000). Prospective study of depression and the risk of heavy alcohol use in women. The American Journal of Psychiatry, 157(5), 751–758. https://doi.org/10.1176/appi.ajp.157.5.751
   PubMed Web of Science ®Google Scholar
• Dreifuss, J. A., Griffin, M. L., Frost, K., Fitzmaurice, G. M., Potter, J. S., Fiellin, D. A., Selzer, J., Hatch-Maillette, M., Sonne, S. C., & Weiss, R. D. (2013). Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study. Drug and Alcohol Dependence, 131(1–2), 112–118. https://doi.org/10.1016/j.drugalcdep.2012.12.010
   PubMed Web of Science ®Google Scholar
• Erfan, S., Hashim, A. H., Shaheen, M., & Sabry, N. (2010). Effect of comorbid depression on substance use disorders. Substance Abuse, 31(3), 162–169. https://doi.org/10.1080/08897077.2010.495311
   PubMed Web of Science ®Google Scholar
• Ferri, M., Finlayson, A. J., Wang, L., & Martin, P. R. (2014). Predictive factors for relapse in patients on buprenorphine maintenance. The American Journal on Addictions, 23(1), 62–67. https://doi.org/10.1111/j.1521-0391.2013.12074.x
   PubMed Web of Science ®Google Scholar
• Gerra, G., Borella, F., Zaimovic, A., Moi, G., Bussandri, M., Bubici, C., & Bertacca, S. (2004). Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug and Alcohol Dependence, 75(1), 37–45. https://doi.org/10.1016/j.drugalcdep.2003.11.017
   PubMed Web of Science ®Google Scholar
• Gerra, G., Leonardi, C., D'Amore, A., Strepparola, G., Fagetti, R., Assi, C., Zaimovic, A., & Lucchini, A. (2006). Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: A retrospective study. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 30(2), 265–272. https://doi.org/10.1016/j.pnpbp.2005.10.007
   PubMed Web of Science ®Google Scholar
• Ghabrash, M. F., Bahremand, A., Veilleux, M., Blais-Normandin, G., Chicoine, G., Sutra-Cole, C., Kaur, N., Ziegler, D., Dubreucq, S., Juteau, L.-C., Lestage, L., & Jutras-Aswad, D. (2020). Depression and outcomes of methadone and buprenorphine treatment among people with opioid use disorders: A literature review. Journal of Dual Diagnosis, 16(2), 191–207. https://doi.org/10.1080/15504263.2020.1726549
   PubMed Web of Science ®Google Scholar
• Havard, A., Teesson, M., Darke, S., & Ross, J. (2006). Depression among heroin users: 12-Month outcomes from the Australian Treatment Outcome Study (ATOS). Journal of Substance Abuse Treatment, 30(4), 355–362. https://doi.org/10.1016/j.jsat.2006.03.012
   PubMed Web of Science ®Google Scholar
• Health Canada. (2019). Canadian Tobacco, Alcogol and Drugs Survey (CTADS): summary of results for 2017. Health Canada.
   Google Scholar
• Hesse, M. (2009). Integrated psychological treatment for substance use and co-morbid anxiety or depression vs. treatment for substance use alone. A systematic review of the published literature. BMC Psychiatry, 9(1), 6. https://doi.org/10.1186/1471-244X-9-6
   PubMedGoogle Scholar
• Jutras-Aswad, D., Le Foll, B., Ahamad, K., Lim, R., Bruneau, J., Fischer, B., Rehm, J., Wild, T. C., Wood, E., Brissette, S., Gagnon, L., Fikowski, J., Ledjiar, O., Masse, B., & Socias, M. E., OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. (2022). Flexible buprenorphine/naloxone model of care for reducing opioid use in individuals with prescription-type opioid use disorder: An open-label, pragmatic, noninferiority randomized controlled trial. The American Journal of Psychiatry, 179(10), 726–739. https://doi.org/10.1176/appi.ajp.21090964
   PubMed Web of Science ®Google Scholar
• Kelly, T. M., & Daley, D. C. (2013). Integrated treatment of substance use and psychiatric disorders. Social Work in Public Health, 28(3–4), 388–406. https://doi.org/10.1080/19371918.2013.774673
   PubMed Web of Science ®Google Scholar
• Kidorf, M., Disney, E. R., King, V. L., Neufeld, K., Beilenson, P. L., & Brooner, R. K. (2004). Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program. Drug and Alcohol Dependence, 74(2), 115–122. https://doi.org/10.1016/j.drugalcdep.2003.11.014
   PubMed Web of Science ®Google Scholar
• Kosten, T. R., Morgan, C., & Kosten, T. A. (1990). Depressive symptoms during buprenorphine treatment of opioid abusers. Journal of Substance Abuse Treatment, 7(1), 51–54. https://doi.org/10.1016/0740-5472(90)90035-o
   PubMed Web of Science ®Google Scholar
• Kosten, T., Falcioni, J., Oliveto, A., & Feingold, A. (2004). Depression predicts higher rates of heroin use on desipramine with buprenorphine than with methadone. The American Journal on Addictions, 13(2), 191–201. https://doi.org/10.1080/10550490490435966
   PubMed Web of Science ®Google Scholar
• Krumme, A. A., Kaigamba, F., Binagwaho, A., Murray, M. B., Rich, M. L., & Franke, M. F. (2015). Depression, adherence and attrition from care in HIV-infected adults receiving antiretroviral therapy. Journal of Epidemiology and Community Health, 69(3), 284–289. https://doi.org/10.1136/jech-2014-204494
   PubMed Web of Science ®Google Scholar
• Laqueille, X., Poirier, M. F., Jalfre, V., Bourdel, M. C., Willard, D., & Olié, J. P. (2001). Predictive factors of response to buprenorphine in the substitutive treatment of heroin addicts. Results of a multicenter study of 73 patients. ]. La Presse Médicale, 30(32), 1581–1585. [
   PubMed Web of Science ®Google Scholar
• Manhapra, A., Rosenheck, R., & Fiellin, D. A. (2017). Opioid substitution treatment is linked to reduced risk of death in opioid use disorder. BMJ (Clinical Research ed.), 357, j1947. https://doi.org/10.1136/bmj.j1947
   PubMedGoogle Scholar
• Marsch, L. A., Stephens, M. A., Mudric, T., Strain, E. C., Bigelow, G. E., & Johnson, R. E. (2005). Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence. Experimental and Clinical Psychopharmacology, 13(4), 293–302. https://doi.org/10.1037/1064-1297.13.4.293
   PubMed Web of Science ®Google Scholar
• McCarty, D., Priest, K. C., & Korthuis, P. T. (2018). Treatment and prevention of opioid use disorder: challenges and opportunities. Annual Review of Public Health, 39(1), 525–541. https://doi.org/10.1146/annurev-publhealth-040617-013526
   PubMed Web of Science ®Google Scholar
• Mocanu, V., Bozinoff, N., Wood, E., Jutras-Aswad, D., Le Foll, B., Lim, R., Cheol Choi, J., Yin Mok, W., & Eugenia Socias, M., OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. (2023). Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial. Drug and Alcohol Dependence, 248, 109932. https://doi.org/10.1016/j.drugalcdep.2023.109932
   PubMed Web of Science ®Google Scholar
• National Academies of Sciences, Engineering, and Medicine. (2017). Pain management and the opioid epidemic: Balancing societal and individual benefits and risks of prescription opioid use. The National Academies Press. https://doi.org/10.17226/24781
   Google Scholar
• Nielsen, S., Bruno, R., Lintzeris, N., Fischer, J., Carruthers, S., & Stoové, M. (2011). Pharmaceutical opioid analgesic and heroin dependence: how do treatment-seeking clients differ in Australia? Drug and Alcohol Review, 30(3), 291–299. https://doi.org/10.1111/j.1465-3362.2011.00302.x
   PubMed Web of Science ®Google Scholar
• Pani, P. P., Maremmani, I., Pirastu, R., Tagliamonte, A., & Gessa, G. L. (2000). Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug and Alcohol Dependence, 60(1), 39–50. https://doi.org/10.1016/s0376-8716(99)00140-4
   PubMed Web of Science ®Google Scholar
• Pedrelli, P., Iovieno, N., Vitali, M., Tedeschini, E., Bentley, K. H., & Papakostas, G. I. (2011). Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis. Journal of Clinical Psychopharmacology, 31(5), 582–586. https://doi.org/10.1097/JCP.0b013e31822c0adf
   PubMed Web of Science ®Google Scholar
• Pettinati, H. M., O'Brien, C. P., & Dundon, W. D. (2013). Current status of co-occurring mood and substance use disorders: A new therapeutic target. The American Journal of Psychiatry, 170(1), 23–30. https://doi.org/10.1176/appi.ajp.2012.12010112
   PubMed Web of Science ®Google Scholar
• Pettinati, H. M., Oslin, D. W., Kampman, K. M., Dundon, W. D., Xie, H., Gallis, T. L., Dackis, C. A., & O'Brien, C. P. (2010). A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. American Journal of Psychiatry, 167(6), 668–675. https://doi.org/10.1176/appi.ajp.2009.08060852
   PubMed Web of Science ®Google Scholar
• Poirier, M. F., Laqueille, X., Jalfre, V., Willard, D., Bourdel, M. C., Fermanian, J., & Olié, J. P. (2004). Clinical profile of responders to buprenorphine as a substitution treatment in heroin addicts: results of a multicenter study of 73 patients. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 28(2), 267–272. https://doi.org/10.1016/j.pnpbp.2003.10.003
   PubMed Web of Science ®Google Scholar
• Rao, S. R., Broome, K. M., & Simpson, D. D. (2004). Depression and hostility as predictors of long-term outcomes among opiate users. Addiction (Abingdon, England), 99(5), 579–589. https://doi.org/10.1111/j.1360-0443.2004.00686.x
   PubMed Web of Science ®Google Scholar
• Ross, J., Ross, J., Teesson, M., Ross, J., Teesson, M., Darke, S., Ross, J., Teesson, M., Darke, S., Lynskey, M., Ross, J., Teesson, M., Darke, S., Lynskey, M., Ali, R., Ross, J., Teesson, M., Darke, S., Lynskey, M., … Cooke, R. (2005). The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS). Drug and Alcohol Review, 24(5), 411–418. https://doi.org/10.1080/09595230500286039
   PubMed Web of Science ®Google Scholar
• Schuckit, M. A. (2016). Treatment of opioid-use disorders. The New England Journal of Medicine, 375(4), 357–368. https://doi.org/10.1056/NEJMra1604339
   PubMed Web of Science ®Google Scholar
• Stein, M. D., Herman, D. S., Kettavong, M., Cioe, P. A., Friedmann, P. D., Tellioglu, T., & Anderson, B. J. (2010). Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons. Journal of Substance Abuse Treatment, 39(2), 157–166. https://doi.org/10.1016/j.jsat.2010.05.014
   PubMed Web of Science ®Google Scholar
• Sullivan, L. E., Fiellin, D. A., & O'Connor, P. G. (2005). The prevalence and impact of alcohol problems in major depression: A systematic review. The American Journal of Medicine, 118(4), 330–341. https://doi.org/10.1016/j.amjmed.2005.01.007
   PubMed Web of Science ®Google Scholar
• Sullivan, M. D. (2018). Depression effects on long-term prescription opioid use, abuse, and addiction. The Clinical Journal of Pain, 34(9), 878–884. https://journals.lww.com/clinicalpain/Fulltext/2018/09000/Depression_Effects_on_Long_term_Prescription.10.aspx
   Web of Science ®Google Scholar
• Teesson, M., Marel, C., Darke, S., Ross, J., Slade, T., Burns, L., Lynskey, M., Memedovic, S., White, J., & Mills, K. L. (2015). Long-term mortality, remission, criminality and psychiatric comorbidity of heroin dependence: 11-year findings from the Australian Treatment Outcome Study. Addiction (Abingdon, England), 110(6), 986–993. https://doi.org/10.1111/add.12860
   PubMed Web of Science ®Google Scholar
• United Nations Office on Drugs and Crime. (2021). Drug market trends: Opioids, Cannabis. World Drug Report 2021. United Nations publication.
   Google Scholar
• Wu, L. T., Woody, G. E., Yang, C., & Blazer, D. G. (2011). How do prescription opioid users differ from users of heroin or other drugs in psychopathology: results from the national epidemiologic survey on alcohol and related conditions. Journal of Addiction Medicine, 5(1), 28–35. https://doi.org/10.1097/ADM.0b013e3181e0364e
   PubMed Web of Science ®Google Scholar